Тадқиқот ишида 235 тарқалган простата бези саратони ташхиси билан даволанган беморлар киритилди. “Максимал андроген блокада” режимидаги гормонотерапия асосида простата безида андрогенларни (антиандроген) ўз рецепторлари билан боғланишни олдини олиш ва андроген синтезини тўсишга (РГЛГ аналоглари - рилизинг гормонни лютиенловчи гормони) қаратилган қўшма даво усули бўлиб, солиштириш йўли билан қиёсий самарадорлик ўрганилди. Простата бези саратонини прогностик омилларни ҳисобга олиб, гормонал даволашни оптимал режимини танлаш натижасида беморларни ҳаёт сифатини яхшилаш билан бирга даво самародорлигини яхшилашга эришдик.
The study included 235 patients with advanced prostate cancer (PCa). There was provided comparative study of the effectiveness of the treatment methods, based on combination of the biosynthesis of androgen suppression (LHRH analogues) and prevent the binding of androgens (anti-androgens) to their receptors in the prostate tissue - hormone "maximal androgen blockade" (MAB). Certain path we select the optimum mode of hormonal therapy, depending on prognostic factors have led to improve treatment outcomes and quality of life of patients with advanced prostate cancer.
| № | Имя автора | Должность | Наименование организации |
|---|---|---|---|
| 1 | Tillashayxov M.N. | ||
| 2 | Yusupov S.X. | ||
| 3 | Boyko E.V. | ||
| 4 | Valiyeva R.M. |
| № | Название ссылки |
|---|---|
| 1 | 1. Bishr M., Boehm K., Trudeau V. Medical management of benign prostatic hyperplasia: Results from a population-based study. // Can Urol Assoc J. -2016. - 10(1-2). - 55-59. 2. Foley C., Mitsiades N. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. // Horm Cancer. – 2016. - 7(2). - 84-103. 3. Chopra S., Rashid P. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions. // Aust Fam Physician. – 2015. - 44(5). - 302-305. 4. Chandrasekar T., Yang J.C., Gao A.C., Evans C.P. Mechanisms of resistance in castrationresistant prostate cancer (CRPC). // Transl Androl Urol. – 2015. - 4(3). - 365-380. 5. Soga N., Kageyama T., Ogura Y., Yamada T., Hayashi N. Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl. // Curr Urol. – 2016. - 9(1). - 31-35. 6. Sun M., Choueiri T.K., Hamnvik O.R. et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of AndrogenDeprivation Therapy. // JAMA Oncol. – 2015. – 23. - 1-8. 7. Hingorani M., Dixit S., Bashir F. et al. Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports. // Cancer Biol Med. – 2014. - 11(4). - 277-280. |